Terrance P. Coyne, EVP & CFO at Royalty Pharma plc (RPRX), sold 139,164 shares at $39.87 ($5.5M) on 2025-12-01, disclosed to the SEC on 2025-12-03.
Scheduled sale ($5.5M) by EVP & CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.87 | 3,750 | $150K | 2.7% |
| 2 | $39.87 | 3,750 | $150K | 2.7% |
| 3 | $39.87 | 65,832 | $2.6M | 47.3% |
| 4 | $39.87 | 65,832 | $2.6M | 47.3% |
| Total | $39.87 avg | 139,164 | $5.5M | 100% |
| Filing → |
| RPRX | SELL | 2026-04-30 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-04-02 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-03-25 | $3.2M | — | Filing → |